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Background: Prostaglandins (PGs), lipid autacoids derived from arachidonic acid, play a pivotal role during in-
ﬂammation. PGD2 synthase is abundantly expressed in heart tissue and PGD2 has recently been found to induce
cardiomyocyte apoptosis. PGD2 is an unstable prostanoidmetabolite; therefore the objective of the present study
was to elucidate whether its ﬁnal dehydration product, 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2, present at high levels in
ischemic myocardium) might cause cardiomyocyte damage.
Methods and results:Using speciﬁc (ant)agonists we show that 15d-PGJ2 induced formation of intracellular reac-
tive oxygen species (ROS) and phosphorylation of p38 and p42/44 MAPKs via the PGD2 receptor DP2 (but not
DP1 or PPARγ) in the murine atrial cardiomyocyte HL-1 cell line. Activation of the DP2-ROS-MAPK axis by
15d-PGJ2 enhanced transcription and translation of TNFα and induced apoptosis in HL-1 cardiomyocytes. Silenc-
ing of TNFα signiﬁcantly attenuated the extrinsic (caspase-8) and intrinsic apoptotic pathways (bax and caspase-
9), caspase-3 activation and downstream PARP cleavage and γH2AX activation. The apoptotic machinery was
unaffected by intracellular calcium, transcription factor NF-κB and its downstream target p53. Of note, 9,10-
dihydro-15d-PGJ2 (lacking the electrophilic carbon atom in the cyclopentenone ring) did not activate cellular re-
sponses. Selected experiments performed in primary murine cardiomyocytes conﬁrmed data obtained in HL-1
cells namely that the intrinsic and extrinsic apoptotic cascades are activated via DP2/MAPK/TNFα signaling.
Conclusions:We conclude that the reactive α,β-unsaturated carbonyl group of 15d-PGJ2 is responsible for the
pronounced upregulation of TNFα promoting cardiomyocyte apoptosis.Wepropose that inhibition of DP2 recep-
tors could provide a possibility to modulate 15d-PGJ2-induced myocardial injury.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cardiovascular diseases are more prevalent worldwide compared to
other diseases, amongst whichmyocardial ischemia caused by coronary
blockage is by far themost frequent cause ofmortality [1,2]. Imbalanced
oxygen demand and supply to cardiomyocytes during coronary artery
disease (CAD) activates cell death cascades and promotes myocardial
infarction (MI) [3]. Advances in treatment based on currently available
targets have failed to change the status of CAD/MI and therefore we
await novel strides in fundamental understanding through which we
might be able to manipulate progression of CAD and MI., Institute of Molecular Biology
tria. Tel.: +43 316 380 4208;
.
nd Ltd. This is an open access article uChanges in fatty acid compositions of myocardial lipids were found
to be associated with CAD and MI [2]. Elevated phospholipase A2
(PLA2) mass and activity, as reported in patients with myocardial ische-
mia [4], lead to accumulation of unesteriﬁed arachidonic acid (AA) from
phospholipids in the heart [5]. As a consequence, increased tissue levels
of prostaglandins (PGs) e.g., PGI2, PGE2, and its isomer PGD2, generated
via cyclooxygenase (COX)-mediated conversion of AA have been
observed in the ischemic myocardium [6]. However, PGD2 is degrad-
ed in vitro and in vivo to a variety of metabolites, the majority of
which were thought, until recently, to be physiologically inactive [7].
PGD2 is either metabolized enzymatically to 13,14-dihydro-15-keto
PGD2 [7] (for chemical structures, see Supplement Fig. I) or readily
dehydrated into J series prostanoids characterized by the presence of
an α,β-unsaturated ketone in the cyclopentenone ring. Particularly
15-deoxy-Δ12,14-PGJ2 (15d-PGJ2, Supplement Fig. I), the ﬁnal dehydra-
tion product of PGD2 has been shown to have broad effects on variousnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/)
473C.N. Koyani et al. / International Journal of Cardiology 173 (2014) 472–480cellular systems [8,9]. 15d-PGJ2 is a potent endogenous ligand for the
peroxisome proliferator-activated-receptor γ (PPARγ), a member of
the nuclear receptor superfamily of ligand-dependent transcription fac-
tors (for review see [10,11]). However, recent ﬁndings conﬁrm that
15d-PGJ2 exerts a variety of cellular responses via PPARγ-independent
mechanisms, e.g. activation of mitogen-activated protein kinases
(MAPKs) [12,13], modulation of Akt and nuclear factor-κB (NF-κB)
[14,15], induction of oxidative stress [16], expression of cytokines [17],
promotion of apoptosis [18,19], up-regulation of antioxidant response
genes [20,21] and modulation of COX-2 [22].
Depending on disease etiology, PGD2 may exert pro- as well as anti-
inﬂammatory effects in different biological systems [23] via two distinct
G-protein coupled receptors, (i) the D-type prostanoid receptor (DP1)
and (ii) the chemoattractant receptor-homologous molecule expressed
on Th2 cells (CRTH2, also named DP2). Although DP1-mediated activi-
ties have also been suggested [24], PGD2-derived metabolites seem to
preferentially interact with DP2 [7].
Abundant DP2 mRNA expression has been found in human heart
[25] and pronounced staining for DP1 and DP2 protein has been found
in murine cardiomyocytes [6]. Qiu and colleagues [6] have recently
reported that PGD2 (but not PGE2 or PGI2) favors cardiomyocyte death
during MI. As high 15d-PGJ2 levels were detected in myocardial tis-
sues subsequent to ischemia–reperfusion injury [26], this bona ﬁde
PGD2 metabolite is likely to act as the leading cause for cardiomyocyte
death during CAD.
Therefore, the aim of this study was to explore whether 15d-PGJ2,
formed in vivo during resolving inﬂammation [24], may interact with
candidate receptors (DP1, DP2 and/or PPARγ) present on cardiomyo-
cytes. Next we were interested in receptor-dependent or -independent
activation of signaling pathways in cardiomyocytes. As 15d-PGJ2 may
modulate cytokine production [17], expression and involvement of can-
didate cytokines that promote inﬂammation and/or apoptosis were
studied. Finally, we sought to clarify structure–activity relationships of
15d-PGJ2 analogs-mediated effects in cardiomyocytes.2. Materials and methods
A detailedMaterials andmethods section on cell culture [27], isolation of primarymu-
rine cardiomyocytes [28], incubation protocols, Western blot analysis [22,29], RNA isola-
tion and real time RT-PCR (qPCR) [30], TNFα RNA interference and silencing [22],
reactive oxygen species (ROS)measurements [31], cell viability assay [31], TNFα ELISA ex-
periments and statistics is available in the online Supplement.3. Results
3.1. 15d-PGJ2 promotes MAPK activation in cardiomyocytes via
intracellular redox imbalance
Treatment of HL-1 cells with increasing 15d-PGJ2 concentrations in-
duced phosphorylation of p38 and p42/44 MAPK (Fig. 1A). As pro-
nounced MAPK activation was observed at 15 μM 15d-PGJ2 (Fig. 1A),
this concentration was chosen for further experiments. Fig. 1B/C show
time-dependent activation of both MAPKs by 15d-PGJ2. Phosphoryla-
tion was detectable after 5 (pp38 MAPK) and 7.5 min (pp42/44
MAPK). MAPK phosphorylation reached maximal levels after 30 min
that persisted up to 8 h. Densitometric and statistical evaluations of im-
munoreactive (non)phosphorylated MAPK signals (Fig. 1A–C) and nor-
malization to β-actin is shown in the Supplement (Fig. II and Fig. IIIA/B).
Total MAPKs and β-actin levels were unaffected by 15d-PGJ2.
Cellular activation by 15d-PGJ2 may induce ROS generation [22,32].
To clarify whether the formation of intracellular ROS in cardiomyocytes
is affected by 15d-PGJ2 the peroxidase-sensitive probeDCFDAwas used.
Upon stimulation signiﬁcantly increased DCF ﬂuorescence was ob-
served acutely after 2.5 min (Fig. 1D). In response to 15d-PGJ2 ROS
levels reached a maximum at 15 min and were 1.4-fold above baseline
levels after 60 min (Fig. 1D).Next, we assessed the effects of antioxidants on 15d-PGJ2-treated
cardiomyocytes. Fig. 1E (upper panel) shows that the antioxidant
PDTC and Tempol (a cell-permeable nitroxide and superoxide anion
scavenger) blunted 15d-PGJ2-induced ROS formation efﬁciently while
NAC (also preferentially reacting with superoxide anions) was less ef-
fective. To test whether the time-dependent increase in ROS formation
(Fig. 1D) precedes MAPK activation, cardiomyocytes were incubated
with ROS scavengers prior to 15d-PGJ2 treatments. Tempol and PDTC
completely blunted p38 and p42/44 MAPK phosphorylation (Fig. 1E,
lower panel) while NAC was again less effective; phosphorylation of
MAPKs was impaired by 40% (p38 MAPK) and 70% (p42/44 MAPK)
(for densitometric evaluations of Western blots see Supplement
Fig. IIIC/D). These ﬁndings suggest that 15d-PGJ2-mediated ROS activa-
tion is upstream of p38 and p42/44 MAPK phosphorylation.
3.2. DP2 mediates ROS production and MAPK activation in cardiomyocytes
in response to 15d-PGJ2
15d-PGJ2-mediated cellular activation may involve receptor-
independent and -dependent pathways [11]. To test involvement of
candidate receptors for ROS production and MAPK activation, HL-1
cells were incubated with three different receptor antagonists/
inhibitors. Fig. 2 shows that CAY10471 (DP2 antagonist) but not
MK0524 (DP1 antagonist) or T0070907 (PPARγ inhibitor) reversed
15d-PGJ2-induced ROS production (upper panel) and MAPK activation
(lower panel) in cardiomyocytes almost to baseline levels (densitomet-
ric evaluations and statistical analyses of Western blots are shown in
Supplement Fig. IVA/B). To reveal whether 15d-PGJ2 impacts on DP2
transcription, cells were stimulated with 15d-PGJ2 up to 8 h prior to
RNA isolation. These experiments revealed that 15d-PGJ2 does not affect
DP2 transcription (Fig. 3A; DP1 receptor expression was analyzed in
parallel) and that ROS formation and MAPK activation are downstream
events of 15d-PGJ2-mediated DP2 engagement. Furthermore, expres-
sion of PPARγ as well as its downstream target transcription factor
NF-κB were not altered by 15d-PGJ2 treatment (Fig. 3B).
3.3. The DP2-ROS-MAPK axis increases TNFα transcription and translation
in 15d-PGJ2-stimulated cardiomyocytes
DP2 plays a central role in pathogenic inﬂammation [33] and 15d-
PGJ2 may promote induction of pro-inﬂammatory proteins under
certain conditions [11]. We observed that mRNA levels of cytokines
(interleukin [IL]-1α, IL-2, IL-6, IL-8, and IL-10) were not altered by
15d-PGJ2 treatments of HL-1 cells (data not shown), while TNFα levels
were highly upregulated on mRNA and protein levels by 3- and 6-fold
(Fig. 4A and B), respectively.
Next, we aimed to elucidate intracellular signaling cascades that
mediate this response. Both, SB203580 and PD98059 (inhibitors of
pp38 MAPK and p42/44MAPK kinase) signiﬁcantly blocked TNFα tran-
scription in response to 15d-PGJ2 (Fig. 4C). Of note, only CAY10471
(DP2 antagonist) but not MK0524 (DP1 antagonist) or T0070907
(PPARγ antagonist) reduced TNFαmRNA and protein expression levels
in response to 15d-PGJ2 (Fig. 4C and D). Supplement Fig. V supports
speciﬁcity and efﬁcacy of the respective inhibitors to block respective
MAPK pathways.
3.4. 15d-PGJ2-mediated TNFα induces the apoptotic machinery in
cardiomyocytes
TNFα has recently been shown to induce cardiomyocyte apoptosis
in vivo [34,35]. This was now investigated in HL-1 cells. 15d-PGJ2 treat-
ment (15 μM) reduced cell viability in a time-dependent manner up to
35% after 8 h (Fig. 5A). Fig. 5B shows activation of the extrinsic (caspase-
8) and intrinsic apoptotic pathways (bax and caspase-9) as well as
induction of caspase-3, the convergence point of both pathways.
Furthermore, downstream events of caspase-3 activation, namely
Fig. 1. 15d-PGJ2 promotesMAPK activation in cardiomyocytes via intracellular redox balance. (A) HL-1 cells were treatedwith indicated concentrations of 15d-PGJ2 for 1 h to follow pp38
and pp42/44MAPK expression byWestern blot. Cells were incubated with 15d-PGJ2 (15 μM) for indicated time periods to follow (B/C) pp38 and pp42/44MAPK expression and (D) ROS
generation byDCFﬂuorescence. Cellswere incubatedwith ROS scavengers (Tempol [1mM],NAC [5mM] or PDTC [1mM]) for 30minprior to 15d-PGJ2 treatments (15 μM) for 1 h to follow
(E, upper panel) ROS generation and (E, lower panel) pp38 and pp42/44 MAPK expression. For Western blot analysis protein lysates were subjected to SDS-PAGE, proteins were trans-
ferred to nitrocellulosemembranes and immunoreactive bandswere visualized using speciﬁc primary and secondary antibodies. For normalization,membraneswere stripped andprobed
with primary antibodies against β-actin aswell as total p38 and p42/44MAPK. One representative blot (A–C and E) out of three is shown. (D) For detection of intracellular ROS levels cells
were incubated with carboxy-H2DCFDA (10 μM) for 30 min after treatment with 15d-PGJ2. DCF ﬂuorescence levels of vehicle (0.1% DMSO)-treated cells were set 100% and values are
expressed as mean ± SEM (n = 6). * p ≤ 0.05 vs. untreated.
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indicator of DNA damage) became apparent (Fig. 5B; densitometric
evaluations and statistical analyses of immunoreactive bands are
shown in Supplement Fig. VIA/B).
As a 4 h treatment of cardiomyocytes with 15d-PGJ2 led to pro-
nounced activation of the apoptotic machinery (Fig. 5B, Supplement
Fig. VIA/B), this time point was chosen for further experiments. To
conﬁrm TNFα as an inducer of cell death, HL-1 cells were transfected
with TNFα-siRNA prior to 15d-PGJ2 treatments (silencing efﬁcacy is
shown in Supplement Fig. VII). Silencing of TNFα restored cell viability
(Fig. 5C) and reduced expression of apoptoticmarkers (Fig. 5D; densito-
metric and statistical evaluations ofWestern blots are shown in Supple-
ment Fig. VIC/D).
To conﬁrm that DP2 is the candidate receptor for 15d-PGJ2-
dependent TNFα synthesis and apoptosis, cardiomyocytes were pre-
treated with speciﬁc antagonists. Only the DP2 inhibitor CAY10471
(but not MK0524 or T0070907) effectively restored cell viability of
15d-PGJ2-treated cardiomyocytes (Fig. 5E). Summarizing these obser-
vations (Figs. 4 and 5), we conclude that 15d-PGJ2 induces cardiomyo-
cyte death pathways through the involvement of the DP2/TNFα axis.
Next, we studied TNF receptor involvement in 15d-PGJ2-mediated
apoptosis. Pharmacological antagonism of TNF receptor 1 and 2 (R-
7050, [35]) inhibited the extrinsic and intrinsic apoptotic pathways(Fig. 5F; densitometric and statistical evaluations of Western blots are
shown in Supplement Fig. VIII).
3.5. 15d-PGJ2-induced signaling is calcium-independent but mediated via
its cyclopentenone ring
The interaction of 15d-PGJ2 with DP2 could promote the pro-
inﬂammatory cascade via alterations in intracellular calcium concen-
trations [11]. To reveal whether this route might be operative in HL-1
cells, the cell permeable Ca2+ chelating agent EGTA-AM was used.
Preincubation of cardiomyocytes with EGTA-AM did not affect 15d-
PGJ2-stimulated TNFα synthesis onmRNA and protein levels suggesting
that the observed pro-inﬂammatory effect is independent of intracellu-
lar calcium homeostasis (Fig. 6A and B).
To get insight into the structural requirements that mediate in-
creased ROS production in cardiomyocytes, two chemical analogs of
15d-PGJ2 were tested. 9,10-Dihydro-15d-PGJ2 lacks the reactive α,β-
unsaturated carbonyl group and an electrophilic carbon atom in the
cyclopentenone system (Supplement Fig. I). 13,14-Dihydro-15-keto
PGD2 further lacks the electrophilic carbon atom and the aliphatic
double bond adjacent to the cyclopentenone system (Supplement
Fig. I). Compared to 15d-PGJ2, treatment with 9,10-dihydro-15d-PGJ2
did alter neither DCF ﬂuorescence (Fig. 6C, upper panel) nor
Fig. 2. DP2 mediates ROS production and MAPK activation in cardiomyocytes in response
to 15d-PGJ2. HL-1 cells were incubated with MK0524 (100 nM), CAY10471 (1 μM) or
T0070907 (20 μM) for 30 min prior to 15d-PGJ2 (15 μM) treatments for 15 min to follow
ROS levels by DCF ﬂuorescence (upper panel) and 1 h to follow pp38 and pp42/44 MAPK
expression (lower panel). For detection of intracellular ROS levels cells were incubated
with carboxy-H2DCFDA (10 μM) for 30 min after treatment with 15d-PGJ2. DCF ﬂuores-
cence levels of vehicle (0.1% DMSO)-treated cells were set 100% and values are expressed
as mean ± SEM (n= 6). * p≤ 0.05 vs. untreated and # p ≤ 0.05 vs. 15d-PGJ2 treated. For
Western blot analysis protein lysates were subjected to SDS-PAGE, proteins were trans-
ferred to nitrocellulosemembranes and immunoreactive bandswere visualized using spe-
ciﬁc primary and secondary antibodies. For normalization, membranes were stripped and
probedwith primary antibodies againstβ-actin aswell as total p38 andp42/44MAPK.One
representative blot out of three is shown.
Fig. 3. Expression of PG receptors DP1, DP2 and PPARγ. HL-1 cells were incubated with
15d-PGJ2 (15 μM) for indicated time periods to follow (A) DP1 and DP2mRNA expression
using qPCR as well as (B) PPARγ and NF-κB protein expression using Western blot. For
mRNA expression cells were lysed, RNAwas isolated and qPCRwas performed using spe-
ciﬁc primers. Values are expressed asmean± SEM (n=6). ForWestern blot analysis pro-
tein lysates were subjected to SDS-PAGE, proteins were transferred to nitrocellulose
membranes and immunoreactive bands were visualized using speciﬁc primary and sec-
ondary antibodies. For normalization,membraneswere stripped and probedwith primary
antibodies against β-actin. One representative blot (B) out of three is shown.
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cardiomyocytes were treated with the DP2 agonist 13,14-dihydro-15-
keto PGD2. These data (Fig. 6C) demonstrate that DP2-mediated ROS
formation and activation of MAPK is due either to the cyclopentenone
ring present in 15d-PGJ2 or to a hydroxycyclopentanone system present
in 13,14-dihydro-15-keto PGD2. Densitometric evaluations and statisti-
cal analyses of Western blots are shown in Supplement Fig. IX.
3.6. 15d-PGJ2 induces apoptosis in primary murine cardiomyocytes via
DP2/MAPK/TNFα signaling
To conﬁrm our ﬁndings obtained in HL-1 cells in a more physiologi-
cal setting, primary murine cardiomyocytes were isolated and selected
experiments were performed. Treatment of primary cardiomyocytes
with increasing 15d-PGJ2 concentrations induced phosphorylation of
p38 and p42/44 MAPK (Fig. 7A) at much lower agonist concentrations
(10–100 nM) when compared to HL-1 cells (15 μM, Fig. 1A). As pro-
nounced MAPK activation was observed at 50 nM 15d-PGJ2 (Fig. 7A),
this concentration was chosen for further experiments. Fig. 7B shows
that 15d-PGJ2 does not affect DP2 transcription (DP1 receptor expres-
sion was analyzed in parallel) while an increase of TNFα mRNA was
observed already at 2 h post treatment. After 8 h, TNFα transcription
was increased by approx. 5-fold. Under these conditions (8 h) TNFα
protein concentrations released by primary cardiomyocytes increased
to approx. 300 pg/ml (vs. 35 pg/ml under basal levels). Preincubation
of cardiomyocytes with the DP2 inhibitor CAY10471 reduced TNFαlevels by 62% (to approx. 105 pg/ml) (Fig. 7C, upper panel). As TNFα
has been shown to induce apoptosis in HL-1 cells (Fig. 5) this was
now tested in primary cardiomyocytes. Fig. 7C (lower panel) shows
15d-PGJ2-mediated activation of the extrinsic (caspase-8) and intrinsic
apoptotic pathways (caspase-9), induction of caspase-3 (the conver-
gence point of both pathways), and PARP cleavage. Pretreatment of
primary cardiomyocytes with CAY10471 partially inhibited caspase-8
and -9 (by approx. 50%) and caspase-3 and PARP cleavage completely
(Fig. 7C, lower panel).
4. Discussion
The development of sarcolemmal membrane injury and the associ-
ated loss of cell viability observed duringmyocardial injury are causally
related to progressive phospholipid degradation [36]. The net loss of
phosphatidylcholine during MI correlates with PLA2-mediated genera-
tion of free AA that can directly induce apoptosis in cardiomyocytes
[37–39] or is fuelled into PG biosynthesis. Clearly, themajority of biolog-
ical effects mediated by AA can be attributed to COX-mediated for-
mation of PGH2 and subsequent isomerization to primary active PG
metabolites by distinct PG synthases. In vivo studies demonstrated
that in cardiomyocytes the PLA2/COX/PGD2 synthase cascade is respon-
sible for PGD2 formation [40] from its precursor PGH2. Expression anal-
ysis revealed that PGD2 synthase is abundant in heart tissue where
immunoreactivity is localized to atrial and ventricular myocytes [41].
Lipid mediators can be either anti- or pro-inﬂammatory depending
on disease etiology, cell type and eicosanoid receptor expression [24].
Not surprisingly, there is also some controversy concerning the out-
come of PGD2 signaling in the heart: While Qiu and coworkers [6]
have reported that PGD2 induces cardiomyocyte apoptosis during MI,
another group [40] suggested that glucocorticoid induction of PGD2 syn-
thase is cardioprotective. This could be due to different signaling cas-
cades or altered downstream metabolism of PGD2.
Fig. 4.DP2-ROS-MAPK signaling increases TNFα transcription and translation in 15d-PGJ2-stimulated cardiomyocytes. HL-1 cells were incubatedwith 15d-PGJ2 (15 μM) for indicated time
periods to follow (A) TNFαmRNA expression by qPCR and (B) TNFα protein concentrations in the cell culture medium by ELISA. Cells were incubated with SB203580 (10 μM), PD98059
(25 μM), MK0524 (100 nM), CAY10471 (1 μM) or T0070907 (20 μM) for 30min prior to 15d-PGJ2 (15 μM) treatment for 4 h to follow (C) TNFαmRNA expression and (D) TNFα protein
concentrations in the cell culturemedium. After treatmentwith 15d-PGJ2 the cell culturemediumwas removed and cellswere lysed to isolate RNA for qPCR analysis using speciﬁc primers
(A/C) (n=6). The cell culturemediumwasused to quantitate TNFα concentrations using ELISA (B/D) (n=3). Values are expressed asmean±SEM. * p≤ 0.05 vs. untreated and # p≤ 0.05
vs. 15d-PGJ2.
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metabolites in vivo [24,42]; someof the species transported in the circu-
lation produce effects at cells/organs distant from the site of PGD2 syn-
thesis [43]. Hirai and colleagues [43] suggested that PGD2 metabolites
such as 13,14-dihydro-15-keto PGD2 and 15d-PGJ2 might play impor-
tant physiological roles that are mediated via DP2. To clarify effects of
15d-PGJ2 on HL-1 cell and primary cardiomyocyte function in vitro we
have used pharmacological and genetic tools. Results from the present
study suggest that 15d-PGJ2, via engagement of DP2, induces ROS pro-
duction and MAPK activation. These events augment TNFα synthesis
that, via autocrine and/or paracrine signaling induces apoptosis in HL-
1 cells and primary cardiomyocytes through activation of extrinsic and
intrinsic apoptosis pathways.
In principle, 15d-PGJ2 can exert its activity via receptor-dependent
and/or -independent pathways [11]. Here we could demonstrate that
15d-PGJ2 signaling is mediated by DP2 (but not DP1 or PPARγ) in a
calcium-independent manner (Fig. 6A/B). DP1 has been primarily re-
ported to regulate dendritic cell function [44] while DP2 was suggested
to promote inﬂammatory pathways [45]. 13,14-Dihydro-15-keto PGD2
is a selective DP2 agonist [46], while little information is available
about the ability of 15d-PGJ2 to stimulate DP1 [24] and/or DP2 receptors
[47].
Results obtained here clearly indicate that 15d-PGJ2-dependent sig-
naling events are mediated via DP2 in HL-1 cells and primary murine
cardiomyocytes. In line, we have observed potent activation of ROS pro-
duction and stimulation of the p38 and p42/44MAPK pathways by 15d-
PGJ2 (Fig. 2).During thepresent studyMAPK activation started at lowmicromolar
concentrations (Fig. 1A). From previous studies it was concluded that
only aminor fraction (approx. 4%) of exogenously added 15d-PGJ2 is bi-
ologically active while the remainder is either trapped or metabolized
[24]. Taking this into account, concentrations of 15 μM 15d-PGJ2 used
for HL-1 cells in the present study result in approx. 20 ng/ml active
compound, a concentration that would parallel levels of at least
5 ng/ml detected under in vivo inﬂammatory conditions [24]. Most
importantly, 15d-PGJ2 concentrations used in primary cardiomyocytes
for activation of MAPK, TNFα induction and subsequent cell death
are in the low nanomolar range (Fig. 7). Thus our in vitro ﬁndings sug-
gest that low agonist concentrations may be operative under in vivo
conditions.
To the best of our knowledge we are the ﬁrst to show that ROS for-
mation aswell as p38 and p42/44MAPK activation (preceding TNFα in-
duction) by 15d-PGJ2 in cardiomyocytes is dependent on its reactive
α,β-unsaturated carbonyl group, as 9,10-dihydro-15d-PGJ2 failed to in-
duce these signaling cascades. Thus, the electrophilic carbon center in
the ring structure makes PGs susceptible to undergo reactions with nu-
cleophiles such as the free sulfhydryl group of cysteine residues located
in reduced glutathione or cellular proteins [10] that so far have not been
characterized in detail during myocardial apoptosis.
In terms of nuclear receptor activation, it was demonstrated that
15d-PGJ2 modulates inﬂammatory markers in neonatal cardiac cells
via PPARγ-dependent and -independent pathways. The observed 15d-
PGJ2-induced effects are independent of DP1- and PPARγ-mediated
pathways in cardiomyocytes. In contrast to previous ﬁndings [32]
Fig. 5. 15d-PGJ2-induced TNFα activates the apoptotic machinery in cardiomyocytes. HL-1 cells were incubated with 15d-PGJ2 (15 μM) for indicated time periods to measure (A) cell
viability usingMTT assay and to follow (B) apoptoticmarkers byWestern blot. Alternatively, cells were transfectedwith scrambled negative control siRNA (si-scr, 40 nM) or siRNA against
TNFα (si-TNFα, 40 nM) for 6 h and grown for 24 h followed by 15d-PGJ2 (15 μM) treatment for 4 h to follow (C) cell viability and (D) apoptotic markers. Cells were incubated with
(E) MK0524 (100 nM), CAY10471 (1 μM), T0070907 (20 μM) or (F) R-7050 (30 μM) for 30 min prior to 15d-PGJ2 (15 μM) treatments for 4 h to follow (E) cell viability and (F) markers
of apoptosis. For Western blot analysis protein lysates were subjected to SDS-PAGE, proteins were transferred to nitrocellulose membranes and immunoreactive bands were visualized
using speciﬁc primary and secondary antibodies. For normalization, membranes were stripped and probed with primary antibody against β-actin. One representative blot out of three
(B, D, and F) is shown. Only cleaved (but not pro-forms) of PARP (cPARP), caspase-3, -8 and -9 are shown. Cell viability was measured following incubating cells with MTT (0.5 mg/ml)
for 30 min after treatment with 15d-PGJ2. Optical density levels of vehicle (0.1% DMSO)-treated cells were set 100% and values are expressed as mean ± SEM (A, C and E) (n = 6).
* p ≤ 0.05 vs. untreated, # p ≤ 0.05 vs. 15d-PGJ2, ** p ≤ 0.05 vs. si-scr and ## p ≤ 0.05 vs. si-scr + 15d-PGJ2.
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the ROS/p53 or ROS/MAPK/p53 axis, phosphorylation of p53 was not
observed in the present study (Supplement Fig. X).
Our ﬁndings suggest that 15d-PGJ2 promotes ROS-dependent p38
and p42/44 MAPK activation (Fig. 1E). The p42/44 MAPK signaling is
thought to promote cell survival under conditions of mild oxidative
stress whereas the stress activated protein kinase p38 seems to induce
cell death as a response to oxidative injury [48]. In line with results of
the present study p38 MAPK activation can induce the extrinsic and
intrinsic pathways of apoptosis although the ultimate outcome of
SAPK signaling cascades appears to be cell context speciﬁc [49]. Oxida-
tive stress-mediated activation of p42/44 MAPK appears to proceed
via Raf activation, thiol modiﬁcation of tyrosine kinase receptors, or
oxidative inactivation of protein phosphatases. The activation of p38
(or more generally the SAPK pathway) by ROS results in apoptosis
where apoptosis-signaling kinase 1 appears to play an important role
as redox sensor for initiation of the SAPK response [49]. Which one ofthese pathways is activated in response to ROS generation in 15d-
PGJ2-treated HL-1 cardiomyocytes or primary cardiomyocytes is cur-
rently unclear andwas not addressed experimentally during the present
study.
15d-PGJ2 suppresses the immune system by PPARγ-mediated acti-
vation of apoptosis in immune cells [50]. Previous studies have shown
that PPARγ ligands including 15d-PGJ2 may inhibit cardiac hypertrophy
in cultured neonatal rat cardiomyocytes [51]. Cardioprotective effects of
15d-PGJ2 include upregulation of PPARγ, expression of heme oxygenase
1, and inhibition of activation of NF-κB during ischemia–reperfusion in-
jury [52]. Furthermore, administration of 15d-PGJ2 suppressed (i) ex-
pression of IL-1 (mRNA and protein level) in experimental
autoimmune myocarditis [53] as well as (ii) LPS-induced expression
of CXC chemokines and ROS-mediated expression of IL-8 (mRNA and
protein level) in rat cardiomyocytes [54]. The collective results suggest
that 15d-PGJ2 acts sequentially through PPARγ activation, IκB induction,
blockage of NF-κB activation, and inhibition of inﬂammatory cytokine
Fig. 6. 15d-PGJ2-induced signaling is calcium-independent and mediated via its cyclopentenone ring. HL-1 cells were incubated with EGTA-AM (50 μM) for 30 min prior to 15d-PGJ2
(15 μM) treatment for 4 h to follow (A) intracellular TNFαmRNA expression and (B) TNFα protein concentrations in the cell supernatant. After treatment with 15d-PGJ2 the cell culture
mediumwas removed and cellswere lysed to isolate RNA for qPCRanalysis (A, n=6)using speciﬁc primers. The cell culturemediumwas used for TNFαquantiﬁcation by ELISA (B, n=3).
Alternatively, cellswere incubatedwith 15d-PGJ2 (15 μM), 9,10-dihydro-15d-PGJ2 (dh-15d-PGJ2, 15 μM)or 13,14-dihydro-15-keto PGD2 (dk-PGD2, 1 μM) for 1 h to follow (C, upper panel)
ROS levels by DCFﬂuorescence and (C, lower panel) pp38 and pp42/44MAPK expression. ForWestern blot analysis protein lysateswere subjected to SDS-PAGE, proteinswere transferred
to nitrocellulose membranes and immunoreactive bands were visualized using speciﬁc primary and secondary antibodies. For normalization, membranes were stripped and probed with
primary antibodies against total p38 and p42/44 MAPK. One representative blot (C, lower panel) out of three is shown. * p ≤ 0.05 vs. untreated.
Fig. 7. 15d-PGJ2 induces apoptotic pathways in primary murine cardiomyocytes. (A) Cardiomyocytes were treated with indicated concentrations of 15d-PGJ2 for 1 h to follow pp38 and
pp42/44 MAPK expression by Western blot. (B/C) Primary cardiomyocytes were incubated with 15d-PGJ2 (50 nM) (B) for indicated time periods to follow TNFαmRNA expression by
qPCR, or (C) for 8 h to follow TNFα protein concentrations in the cell culture medium (upper panel) and markers of apoptosis (lower panel). For Western blot analysis protein lysates
were subjected to SDS-PAGE, proteinswere transferred to nitrocellulosemembranes and immunoreactive bandswere visualized using speciﬁc primary and secondary antibodies. For nor-
malization,membranes were stripped and probedwith a primary antibody against β-actin. One representative blot out of two (A and C, lower panel) is shown. Only cleaved (but not pro-
forms) of PARP (cPARP), caspase-3, -8 and -9 are shown. After treatment with 15d-PGJ2 the cell culture mediumwas removed and cells were lysed to isolate RNA for qPCR analysis using
speciﬁc primers (B) (n= 3). The cell culturemediumwas used for quantitation of TNFα by ELISA (C, upper panel) (n= 3). Values are expressed asmean± SEM. * p≤ 0.05 vs. untreated
and # p ≤ 0.05 vs. 15d-PGJ2.
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Fig. 8. Summary of 15d-PGJ2-induced signaling events in cardiomyocytes observed during
the present study.
479C.N. Koyani et al. / International Journal of Cardiology 173 (2014) 472–480expression [55]. However, such an anti-inﬂammatory mechanism in-
volving modulation of PPARγ (Figs. 2 and 3) and NF-κB (Fig. 3) was
not observed in the present study.
A series of studies conﬁrmed thatMI is accompanied bymyocyte ap-
optosis (for review see [56]). 15d-PGJ2 attenuated anti-apoptotic effects
of endothelin-1 in primary rat cardiomyocytes [57]. Importantly, in-
ﬂammatory cytokines derived from circulating blood cells [58] or local
synthesis are inducers of the apoptotic machinery in cardiomyocytes.
Among these, IL-1 [59,60], IL-6 [61,62], IL-17 [63] and TNFα [64–66]
are the most potent mediators of cardiomyocyte apoptosis and cardiac
remodeling. Our observations that TNFα is highly upregulated in 15d-
PGJ2-stimulated HL-1 cells as well as primary cardiomyocytes and that
pharmacological aswell as genetic interferencewith this pathway effec-
tively impairs extrinsic/intrinsic apoptotic routes (Figs. 5D/F; 7C) are in
line with these observations. In vivo, heart speciﬁc overexpression of
secretable TNFα in mice augmented cardiomyocyte apoptosis through
activation of multiple death pathways [34]. Thus, the contribution of in-
ﬂammatory cells on 15d-PGJ2-induced pro-inﬂammatory cascades in
cardiomyocytes under in vivo conditions remains to be elucidated.
Cardiac myocyte apoptosis has been identiﬁed as a mechanism of
cell death during CAD and MI. The incidence of apoptosis varies signiﬁ-
cantly and the exact pathophysiological events and underlying signaling
(mostly overlapping) pathways induced by inﬂammatory cytokines still
remain to be clariﬁed in detail for effective therapeutic treatment. Acti-
vation of TNFα is undoubtedly one of the major causes for myocardial
apoptosis leading to cardiac remodeling through multiple routes. We
here show engagement of 15d-PGJ2, a dehydration product of PGD2, in
this process. Experimental work performed during the present study
suggests that the DP2-ROS-MAPK axis plays a central role in this signal-
ing circuit that ultimately leads to cardiomyocyte death via TNFα
(Fig. 8). Both, p38 and p42/44MAPK inhibitorswere found to be equally
effective to attenuate TNFα synthesis in cardiomyocytes in response to
15d-PGJ2 (Fig. 4C).
Previous studies clearly revealed that inhibition/antagonism of TNF
represents one option to reduce cell death in the myocardium. How-
ever, TNF blockage would not prevent upstream engagement of
DP2, generation of ROS and activation of the MAPK pathways that in
turn might adversely affect other signaling cascades. From the present
study (Fig. 8) it seems conclusive that blockage of DP2 receptors
might serve as a novel and potential target to alleviatemyocardial injuryin response to COX-derived eicosanoids e.g. PGD2 and its dehydration
product 15d-PGJ2 during CAD andMI. Data of the present study, togeth-
er with the reported high expression of DP2mRNA in human heart [25]
suggest that DP2 antagonism could provide a potential pharmacological
approach to interfere with PGD2-/15d-PGJ2-mediated cardiomyocyte
injury.
Acknowledgements
HL-1 cells were provided by Dr. Claycomb (New Orleans, LA, USA).
This work was supported by the FWF (SFB-LIPOTOX F3007 and
W1241; C.N.K. was funded by W1226-B18 within the DK-MCD at the
MUG).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2014.03.086.
References
[1] Agrawal R, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of car-
diac hypertrophy. Pharmacol Res 2010;61:269–80.
[2] Kalra BS, Roy V. Efﬁcacy of metabolic modulators in ischemic heart disease: an over-
view. J Clin Pharmacol 2012;52:292–305.
[3] Dumont EA, Hofstra L, van Heerde WL, et al. Cardiomyocyte death induced by myo-
cardial ischemia and reperfusion: measurement with recombinant human annexin-
V in a mouse model. Circulation 2000;102:1564–8.
[4] Ryu SK, Mallat Z, Benessiano J, et al. Phospholipase A2 enzymes, high-dose atorva-
statin, and prediction of ischemic events after acute coronary syndromes. Circulation
2012;125:757–66.
[5] Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Cytochrome P450 and
arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury
revisited. Cardiovasc Res 2005;68:18–25.
[6] Qiu H, Liu JY, Wei D, et al. Cardiac-generated prostanoids mediate cardiac myocyte
apoptosis after myocardial ischaemia. Cardiovasc Res 2012;95:336–45.
[7] Powell WS. 15-Deoxy-delta, 12,14-PGJ2: endogenous PPARgamma ligand or minor
eicosanoid degradation product? J Clin Invest 2003;112:828–30.
[8] Schuligoi R, Schmidt R, Geisslinger G, Kollroser M, Peskar BA, Heinemann A. PGD2
metabolism in plasma: kinetics and relationship with bioactivity on DP1 and
CRTH2 receptors. Biochem Pharmacol 2007;74:107–17.
[9] Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K. 15-deoxy-delta
12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inﬂamma-
tory processes. J Biol Chem 2002;277:10459–66.
[10] Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological ac-
tivities and cellular targets. Med Res Rev 2001;21:185–210.
[11] Zhang X, Young HA. PPAR and immune system—what do we know? Int
Immunopharmacol 2002;2:1029–44.
[12] Lim HJ, Lee KS, Lee S, et al. 15d-PGJ2 stimulates HO-1 expression through p38 MAP
kinase and Nrf-2 pathway in rat vascular smooth muscle cells. Toxicol Appl
Pharmacol 2007;223:20–7.
[13] Lee SJ, Kim MS, Park JY, Woo JS, Kim YK. 15-Deoxy-delta 12,14-prostaglandin J2
induces apoptosis via JNK-mediated mitochondrial pathway in osteoblastic cells.
Toxicology 2008;248:121–9.
[14] Jung WK, Park IS, Park SJ, et al. The 15-deoxy-Delta12,14-prostaglandin J2 inhibits
LPS-stimulated AKT and NF-kappaB activation and suppresses interleukin-6 in
osteoblast-like cells MC3T3E-1. Life Sci 2009;85:46–53.
[15] Giri S, Rattan R, Singh AK, Singh I. The 15-deoxy-delta12,14-prostaglandin J2 inhibits
the inﬂammatory response in primary rat astrocytes via down-regulating
multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway
independent of peroxisome proliferator-activated receptor gamma. J Immunol
2004;173:5196–208.
[16] Kim EH, Na HK, Kim DH, et al. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2
expression through Akt-driven AP-1 activation in human breast cancer cells: a po-
tential role of ROS. Carcinogenesis 2008;29:688–95.
[17] Chiba T, Ueki S, Ito W, et al. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces IL-8
and GM-CSF in a human airway epithelial cell line (NCI-H292). Int Arch Allergy
Immunol 2009;149(Suppl. 1):77–82.
[18] Shen ZN, Nishida K, Doi H, et al. Suppression of chondrosarcoma cells by 15-deoxy-
Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and
p21. Biochem Biophys Res Commun 2005;328:375–82.
[19] Haskew-Layton RE, Payappilly JB, Xu H, Bennett SA, Ratan RR. 15-Deoxy-Delta12,14-
prostaglandin J2 (15d-PGJ2) protects neurons from oxidative death via an Nrf2
astrocyte-speciﬁc mechanism independent of PPARgamma. J Neurochem 2013;124:
536–47.
[20] Ferguson HE, Kulkarni A, Lehmann GM, et al. Electrophilic peroxisome proliferator-
activated receptor-gamma ligands have potent antiﬁbrotic effects in human lung ﬁ-
broblasts. Am J Respir Cell Mol Biol 2009;41:722–30.
[21] Kim JW, Li MH, Jang JH, et al. 15-Deoxy-Delta(12,14)-prostaglandin J(2) rescues
PC12 cells from H2O2-induced apoptosis through Nrf2-mediated upregulation of
480 C.N. Koyani et al. / International Journal of Cardiology 173 (2014) 472–480heme oxygenase-1: potential roles of Akt and ERK1/2. Biochem Pharmacol
2008;76:1577–89.
[22] Kitz K, Windischhofer W, Leis HJ, Huber E, Kollroser M, Malle E. 15-Deoxy-
Delta12,14-prostaglandin J2 induces Cox-2 expression in human osteosarcoma
cells through MAPK and EGFR activation involving reactive oxygen species. Free
Radic Biol Med 2011;50:854–65.
[23] Ricciotti E, FitzGerald GA. Prostaglandins and inﬂammation. Arterioscler Thromb
Vasc Biol 2011;31:986–1000.
[24] Rajakariar R, Hilliard M, Lawrence T, et al. Hematopoietic prostaglandin D2 synthase
controls the onset and resolution of acute inﬂammation through PGD2 and 15-
deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 2007;104:20979–84.
[25] Sawyer N, Cauchon E, Chateauneuf A, et al. Molecular pharmacology of the human
prostaglandin D2 receptor, CRTH2. Br J Pharmacol 2002;137:1163–72.
[26] Lotz C, Lange M, Redel A, et al. Peroxisome-proliferator-activated receptor gamma
mediates the second window of anaesthetic-induced preconditioning. Exp Physiol
2011;96:317–24.
[27] ClaycombWC, Lanson Jr NA, Stallworth BS, et al. HL-1 cells: a cardiac muscle cell line
that contracts and retains phenotypic characteristics of the adult cardiomyocyte.
Proc Natl Acad Sci U S A 1998;95:2979–84.
[28] Sacherer M, Sedej S, Wakula P, et al. JTV519 (K201) reduces sarcoplasmic reticulum
Ca(2)(+) leak and improves diastolic function in vitro in murine and human non-
failing myocardium. Br J Pharmacol 2012;167:493–504.
[29] Rauh A, Windischhofer W, Kovacevic A, et al. Endothelin (ET)-1 and ET-3 promote
expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-
mediated G(i)- and G(q)-pathways and MAP kinase activation. Br J Pharmacol
2008;154:13–24.
[30] Rossmann C, Rauh A, Hammer A, et al. Hypochlorite-modiﬁed high-density lipopro-
tein promotes induction of HO-1 in endothelial cells via activation of p42/44 MAPK
and zinc ﬁnger transcription factor Egr-1. Arch Biochem Biophys 2011;509:16–25.
[31] Semlitsch M, Shackelford RE, Zirkl S, Sattler W, Malle E. ATM protects against
oxidative stress induced by oxidized low-density lipoprotein. DNA Repair (Amst)
2011;10:848–60.
[32] Ho TC, Chen SL, Yang YC, et al. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces vas-
cular endothelial cell apoptosis through the sequential activation of MAPKS and p53.
J Biol Chem 2008;283:30273–88.
[33] Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-type prostanoid receptor antag-
onists as novel therapeutic agents for inﬂammatory diseases. Pharmacology
2010;85:372–82.
[34] Haudek SB, Taffet GE, Schneider MD, Mann DL. TNF provokes cardiomyocyte apo-
ptosis and cardiac remodeling through activation of multiple cell death pathways.
J Clin Invest 2007;117:2692–701.
[35] Gururaja TL, Yung S, Ding R, et al. A class of small molecules that inhibit TNFalpha-
induced survival and death pathways via prevention of interactions between
TNFalphaRI, TRADD, and RIP1. Chem Biol 2007;14:1105–18.
[36] Das DK, Engelman RM, Rousou JA, Breyer RH, Otani H, Lemeshow S. Role of mem-
brane phospholipids in myocardial injury induced by ischemia and reperfusion.
Am J Physiol 1986;251:H71–9.
[37] Chien KR, Han A, Sen A, Buja LM, Willerson JT. Accumulation of unesteriﬁed arachi-
donic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine
deacylation-reacylation cycle and the depletion of membrane phospholipids. Circ
Res 1984;54:313–22.
[38] Chien KR, Sen A, Reynolds R, et al. Release of arachidonate from membrane
phospholipids in cultured neonatal rat myocardial cells during adenosine triphos-
phate depletion. Correlation with the progression of cell injury. J Clin Invest
1985;75:1770–80.
[39] Leong LL, Sturm MJ, Ismail Y, Stephens CJ, Taylor RR. Plasma phospholipase A2
activity in clinical acute myocardial infarction. Clin Exp Pharmacol Physiol
1992;19:113–8.
[40] Tokudome S, Sano M, Shinmura K, et al. Glucocorticoid protects rodent hearts from
ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-
derived PGD2 biosynthesis. J Clin Invest 2009;119:1477–88.
[41] Eguchi Y, Eguchi N, Oda H, et al. Expression of lipocalin-type prostaglandin D syn-
thase (beta-trace) in human heart and its accumulation in the coronary circulation
of angina patients. Proc Natl Acad Sci U S A 1997;94:14689–94.
[42] Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis
of 15-deoxy-delta, 12,14–PGJ2 and the ligation of PPARgamma. J Clin Invest
2003;112:945–55.
[43] Hirai H, Abe H, Tanaka K, et al. Gene structure and functional properties of mouse
CRTH2, a prostaglandin D2 receptor. Biochem Biophys Res Commun 2003;307:
797–802.[44] Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN. Prosta-
glandin D2 inhibits airway dendritic cell migration and function in steady state con-
ditions by selective activation of the D prostanoid receptor 1. J Immunol 2003;171:
3936–40.
[45] Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y. Pronounced
eosinophilic lung inﬂammation and Th2 cytokine release in human lipocalin-type
prostaglandin D synthase transgenic mice. J Immunol 2002;168:443–9.
[46] HatanakaM, Shibata N, Shintani N, et al. 15d-prostaglandin J2 enhancement of nerve
growth factor-induced neurite outgrowth is blocked by the chemoattractant
receptor- homologous molecule expressed on T-helper type 2 cells (CRTH2) antag-
onist CAY10471 in PC12 cells. J Pharmacol Sci 2010;113:89–93.
[47] Monneret G, Li H, Vasilescu J, Rokach J, Powell WS. 15-Deoxy-delta 12,14-prosta-
glandins D2 and J2 are potent activators of human eosinophils. J Immunol
2002;168:3563–9.
[48] Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redox-regulated apopto-
sis signaling. Antioxid Redox Signal 2005;7:472–81.
[49] Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell
survival. Antioxid Redox Signal 2008;10:1343–74.
[50] Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T
lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001;31:
1098–105.
[51] Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated
receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circula-
tion 2001;104:1670–5.
[52] Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-
activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
FASEB J 2002;16:1027–40.
[53] Yuan Z, Liu Y, Liu Y, et al. Peroxisome proliferation-activated receptor-gamma li-
gands ameliorate experimental autoimmune myocarditis. Cardiovasc Res 2003;59:
685–94.
[54] Liu J, Xia Q, Zhang Q, et al. Peroxisome proliferator-activated receptor-gamma li-
gands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl
peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine ex-
pression in neonatal rat cardiac myocytes. Shock 2009;32:317–24.
[55] Yuan Z, Liu Y, Liu Y, et al. Cardioprotective effects of peroxisome proliferator activat-
ed receptor gamma activators on acutemyocarditis: anti-inﬂammatory actions asso-
ciated with nuclear factor kappaB blockade. Heart 2005;91:1203–8.
[56] Bartling B, Holtz J, Darmer D. Contribution of myocyte apoptosis to myocardial in-
farction? Basic Res Cardiol 1998;93:71–84.
[57] Ehara N, Hasegawa K, Ono K, et al. Activators of PPARgamma antagonize protection
of cardiac myocytes by endothelin-1. Biochem Biophys Res Commun 2004;321:
345–9.
[58] Arras M, Strasser R, Mohri M, et al. Tumor necrosis factor-alpha is expressed by
monocytes/macrophages following cardiac microembolization and is antagonized
by cyclosporine. Basic Res Cardiol 1998;93:97–107.
[59] Suzuki K, Murtuza B, Smolenski RT, et al. Overexpression of interleukin-1 receptor
antagonist provides cardioprotection against ischemia–reperfusion injury associated
with reduction in apoptosis. Circulation 2001;104:I308-13.
[60] Nishikawa K, Yoshida M, Kusuhara M, et al. Left ventricular hypertrophy in mice
with a cardiac-speciﬁc overexpression of interleukin-1. Am J Physiol Heart Circ
Physiol 2006;291:H176–83.
[61] Zhang H, Wang HY, Bassel-Duby R, et al. Role of interleukin-6 in cardiac inﬂamma-
tion and dysfunction after burn complicated by sepsis. Am J Physiol Heart Circ Phys-
iol 2007;292:H2408–16.
[62] Matsushita K, Iwanaga S, Oda T, et al. Interleukin-6/soluble interleukin-6 receptor
complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest
2005;85:1210–23.
[63] Liao YH, Xia N, Zhou SF, et al. Interleukin-17A contributes to myocardial ischemia/
reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil inﬁltra-
tion. J Am Coll Cardiol 2012;59:420–9.
[64] Kubota T, Miyagishima M, Frye CS, et al. Overexpression of tumor necrosis factor-
alpha activates both anti- and pro-apoptotic pathways in the myocardium. J Mol
Cell Cardiol 2001;33:1331–44.
[65] Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice
with cardiac-speciﬁc overexpression of tumor necrosis factor-alpha. Circ Res
1997;81:627–35.
[66] Engel D, Peshock R, Armstong RC, Sivasubramanian N, Mann DL. Cardiac myocyte
apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted
TNF overexpression. Am J Physiol Heart Circ Physiol 2004;287:H1303–11.
